CUA Educational Content

Advancement in the management of Von Hippel Landau (VHL) Disease: A Comprehensive Educational Program on hypoxia-inducible factor-2 alpha inhibitor (HIF-2a)

Moderator: Simon Tanguay

Speakers: Shereen Ezzat & Maryam Soleimani


By participating in this learning program, healthcare providers can expect to:

  • Discuss the mechanism of action of HIF-2α inhibitors in suppressing tumor growth in VHL-related tumors.
  • Examine the clinical efficacy and safety profile of HIF-2α inhibitors and impact on clinical practice.
  • Explore strategies for early identification and management of side effects associated with HIF-2α inhibitors, based


This activity is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by CUA. You may claim a maximum of 1 hour of credit.


This program has received financial support in the form of an educational grant from Merck.